Formoterol delivered by Turbuhaler: in pediatric asthma

Abstract

Formoterol is an inhaled long-acting beta(2)-adrenoceptor agonist, with a rapid onset of action and a bronchodilator effect that lasts for at least 12 hours. As add-on therapy to anti-inflammatory medication (e.g. corticosteroids), formoterol 4.5 and 9 microg twice daily delivered by Turbuhaler for 3 months significantly improved lung function (change from baseline in forced expiratory volume in 1 second and/or peak expiratory flow) compared with placebo in randomised, double-blind trials in pediatric patients (aged 6-17 years). In addition, formoterol 9 microg twice daily for 12 weeks reduced the use of rescue medication compared with salmeterol 50 microg twice daily in a nonblind trial in pediatric patients (aged 7-16 years). Single-dose formoterol 4.5 or 9 microg delivered by Turbuhaler provided significant prophylaxis against exercise-induced bronchoconstriction compared with placebo, and demonstrated a longer duration of effect than terbutaline, in a randomized, double-blind, crossover trial in pediatric patients (aged 8-17 years). Formoterol delivered by Turbuhaler was well tolerated in pediatric patients, with respiratory infection being the most commonly reported adverse event.